Evidence map›Paper›PMID 36762930›Full record

ArticleAIDS research and human retroviruses2023

Mixed Origins: HIV gp120-Specific Memory Develops from Pre-Existing Memory and Naive B Cells Following Vaccination in Humans.

Madhubanti Basu, Christopher Fucile, Michael S Piepenbrink, Catherine A Bunce, Li-Xing Man, Jane Liesveld, Alexander F Rosenberg, Michael C Keefer, James J Kobie

Registry-linked trialOpen access · greenAbstract read
In one paragraph

Article in AIDS research and human retroviruses, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02207920 (A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02207920 phase1completednot on this map

A Phase 1b Clinical Trial to Evaluate the Safety and Immunogenicity of Different Combinations of DNA-HIV-PT123 and AIDSVAX® B/E in Healthy, HIV Uninfected Adult Participants

TypeinterventionalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2014 to 2015Enrolled104ConditionsHIV InfectionsArmsAIDSVAX B/E Vaccine, DNA-HIV-PT123 Vaccine, Placebo for DNA-HIV-PT123, Placebo for AIDSVAX B/E
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Madhubanti BasuInfectious Diseases Division and University of Alabama at Birmingham, Birmingham, Alabama, USA.
Christopher FucileInformatics Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Michael S PiepenbrinkInfectious Diseases Division and University of Alabama at Birmingham, Birmingham, Alabama, USA.
Catherine A BunceInfectious Diseases Division, University of Rochester, Rochester, New York, USA.
Li-Xing ManDepartment of Otolaryngology Head and Neck Surgery, and University of Rochester, Rochester, New York, USA.
Jane LiesveldDivision of Hematology/Oncology, University of Rochester, Rochester, New York, USA.
Alexander F RosenbergInformatics Institute, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Michael C KeeferInfectious Diseases Division, University of Rochester, Rochester, New York, USA.
James J KobieInfectious Diseases Division and University of Alabama at Birmingham, Birmingham, Alabama, USA.ORCID 0000-0001-8069-0272
University of Alabama at Birmingham · USUniversity of Rochester · US

Funding

Virology CoreP30AI027767 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Latesha Ellen Elopre · 1988 to 2026
$84.1M
A-Z Clinical Trials UnitUM1AI069452 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Paul A. Goepfert · 2012 to 2026
$28.8M
Virology/Immunology CoreP30AI078498 · NIAID · UNIVERSITY OF ROCHESTER · PI DEWHURST, STEPHEN · 2008 to 2018
$14.6M
Units for HIV/AIDS Clinical Trials NetworksU01AI069511 · NIAID · UNIVERSITY OF ROCHESTER · PI KEEFER, MICHAEL C · 2007 to 2011
$12.0M
Targeting tonsillar B cells for the induction of effective mucosal immunity to HIVR01DE027245 · NIDCR · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2017 to 2021
$3.7M
Targeting IgM Memory to Establish Protective B Cell Responses to HIVR01AI117787 · NIAID · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2015 to 2018
$2.7M
The Origin and Fate of Human HIV-Specific Plasma Cells Following VaccinationR21AI116285 · NIAID · UNIVERSITY OF ROCHESTER · PI KOBIE, JAMES J · 2015 to 2016
$422k
NIAID NIH HHS P30 AI027767NIAID NIH HHS P30 AI078498NIAID NIH HHS R01 AI117787NIAID NIH HHS R21 AI116285NIAID NIH HHS U01 AI069511NIAID NIH HHS UM1 AI069452NIDCR NIH HHS R01 DE027245
6 · The paper itself

Abstract

The most potent and broad HIV envelope (Env)-specific antibodies often when reverted to their inferred germline versions representing the naive B cell receptor, fail to bind Env, suggesting that the initial responding B cell population not only exclusively comprises a naive population, but also a pre-existing cross-reactive antigen-experienced B cell pool that expands following Env exposure. Previously we isolated gp120-reactive monoclonal antibodies (mAbs) from participants in HVTN 105, an HIV vaccine trial. Using deep sequencing, focused on immunoglobulin G (IgG), IgA, and IgM, VH-lineage tracking, we identified four of these mAb lineages in pre-immune peripheral blood. We also looked through the ∼7 month postvaccination bone marrow, and interestingly, several of these lineages that were found in prevaccination blood were still persistent in the postvaccination bone marrow, including the CD138+ long-lived plasma cell compartment. The majority of the pre-immune lineage members included IgM, however, IgG and IgA members were also prevalent and exhibited somatic hypermutation. These results suggest that vaccine-induced gp120-specific antibody lineages originate from both naive and cross-reactive memory B cells. ClinicalTrials.gov NCT02207920.

Indexed as

AIDS VaccinesHIV-1HIV InfectionsAntibodies, MonoclonalAntibodies, NeutralizingHIV AntibodiesHIV Envelope Protein gp120HumansImmunoglobulin AImmunoglobulin GImmunoglobulin MVaccinationAIDS VaccinesAntibodies, MonoclonalAntibodies, NeutralizingHIV AntibodiesHIV Envelope Protein gp120Immunoglobulin AImmunoglobulin GImmunoglobulin Mantibody repertoireB cellenvelopegp120HIV-1memorynaivepre-immune

Identifiers

PMID36762930
PMCPMC10398743
OpenAlexW4319812771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.